Where personal data is transferred outside the EEA, this will only take place in countries for which the European Commission has decided that they ensure an adequate level of protection, or where Standard Contractual Clauses (SCCs) have been implemented
The findings show that patients who underwent sleeve gastrectomy or gastric bypass lost approximately five times more weight over two years than those taking GLP-1 medications.

Markets Europe Markets China Markets Asia Markets World Markets Currencies Prediction Markets Cryptocurrency Futures & Commodities Bonds Funds & ETFs Business Economy Finance Health & Science Media Real Estate Energy Climate Transportation Investigations Industrials Retail Wealth Sports Life Small Business Investing Personal Finance Fintech Financial Advisors Options Action ETF Street Buffett Archive Earnings Trader Talk Tech Cybersecurity AI Enterprise Internet Media Mobile Social Media CNBC Disruptor 50 Tech Guide Politics White House Policy Defense Congress Expanding Opportunity Europe Politics China Politics Asia Politics World Politics Video Latest Video Full Episodes Livestream Top Video Live Audio Europe TV Asia TV CNBC Podcasts CEO Interviews Digital Originals Watchlist Investing Club Trust Portfolio Analysis Trade Alerts Meeting Videos Homestretch Jim's Columns Education Subscribe PRO Pro News Josh Brown Mike Santoli Calls of the Day My Portfolio Livestream Full Episodes Stock Screener Market Forecast Options Investing Chart Investing Subscribe Livestream Make It select USA INTL Livestream Livestream Watchlist SIGN IN Create free account Markets Business Investing Tech Politics Video Watchlist Investing Club PRO Livestream watch now Share Squawk on the Street CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid

Ozempic Face can be characterized with hollow cheeks, sunken eyes, and sagging skin, due to rapid weight loss , or fat loss, from the medication
However, the announcement from health officials says the new low prices for the federal insurance program will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities [co-occurring diseases] for the first time. Beneficiaries who will be eligible for lower-cost GLP-1 medications include individuals with a body mass index (BMI) of 27 or greater who have prediabetes or a history of cardiovascular disease
The negative